Darifenacin hydrobromide

Darifenacin hydrobromide is a type of medication used primarily for the treatment of overactive bladder. It belongs to a class of drugs known as antimuscarinics, which work by blocking the action of acetylcholine, a neurotransmitter involved in the contraction of smooth muscles.

Pharmacology[edit | edit source]

Darifenacin hydrobromide acts as a competitive antagonist at muscarinic acetylcholine receptors, specifically M3 receptors. These receptors are found in the bladder, gastrointestinal tract, and sweat glands. By blocking the action of acetylcholine at these receptors, darifenacin hydrobromide reduces involuntary bladder contractions, thereby reducing the symptoms of overactive bladder.

Clinical Use[edit | edit source]

Darifenacin hydrobromide is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is typically administered orally, in the form of a tablet, and is available in two strengths: 7.5 mg and 15 mg.

Side Effects[edit | edit source]

Common side effects of darifenacin hydrobromide include dry mouth, constipation, and blurred vision. Less common side effects can include urinary tract infection, indigestion, and abdominal pain. As with all medications, the potential benefits must be weighed against the potential risks before use.

Contraindications[edit | edit source]

Darifenacin hydrobromide is contraindicated in patients with urinary or gastric retention, uncontrolled narrow-angle glaucoma, or hypersensitivity to darifenacin hydrobromide or any component of the product.

Interactions[edit | edit source]

Darifenacin hydrobromide can interact with other medications, including certain antifungal and antibiotic medications. It is important for patients to inform their healthcare provider of all medications they are currently taking.